Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Costa Bachas

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Cytometry. Part B, Clinical Cytometry|September 28, 2023
Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometryJesse M Tettero, Naveen Dakappagari, Maaike E Heidinga, et al.
Blood|July 2, 2010
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicineCosta Bachas, Gerrit Jan Schuurhuis, Iris H I M Hollink, et al.
Cytometry. Part B, Clinical Cytometry|August 23, 2024
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cellsTom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, et al.
Leukemia|December 10, 2025
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemiaLukas H Haaksma, Raffaele Palmieri, Tom Reuvekamp, et al.
Haematologica|April 6, 2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survivalJesse M Tettero, Lok Lam Ngai, Costa Bachas, et al.
American Journal of Hematology|March 19, 2026
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive ChemotherapyLukas H Haaksma, Tom Reuvekamp, Kasper J Croese, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Cytometry. Part B, Clinical Cytometry|September 28, 2023
Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometryJesse M Tettero, Naveen Dakappagari, Maaike E Heidinga, et al.
Blood|July 2, 2010
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicineCosta Bachas, Gerrit Jan Schuurhuis, Iris H I M Hollink, et al.
Cytometry. Part B, Clinical Cytometry|August 23, 2024
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cellsTom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, et al.
Leukemia|December 10, 2025
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemiaLukas H Haaksma, Raffaele Palmieri, Tom Reuvekamp, et al.
Haematologica|April 6, 2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survivalJesse M Tettero, Lok Lam Ngai, Costa Bachas, et al.
American Journal of Hematology|March 19, 2026
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive ChemotherapyLukas H Haaksma, Tom Reuvekamp, Kasper J Croese, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Pageof 4